On 14 April, the company TauRx Therapeutics Ltd announced that the last participant has completed treatment in the blinded phase of its late-stage Phase III clinical trial, LUCIDITY, for the treatment of Alzheimer’s disease (AD). The company will now progress to the data cleaning and analysis phase. Topline results are expected in May. The Lucidity trial is a randomised, double-blind and placebo-controlled study evaluating the safety and efficacy of hydromethylthionine in people with AD encompassing mild cognitive impairment due to AD. Hydromethylthionine (which TauRx refer to under the chemical abbreviation, LMTM) acts by blocking abnormal accumulation of Tau protein in the brain. LUCIDITY is the only late-stage study targeting the tau pathology of AD. "This milestone takes us one step closer to announcing the topline results of our potentially ground-breaking Lucidity study. We're extremely grateful to all who are progressing the trial; the study coordinators and investigators, and most importantly the patients who volunteered to take part.", said Professor Claude Wischik, Executive Chairman and Co-Founder.